InMed Pharmaceuticals (INM) Receivables - Net (2020 - 2025)
InMed Pharmaceuticals' (INM) quarterly Receivables - Net came in at $182967.0 in Q4 2025, down 30.32% year-on-year from $262569.0 in Q4 2024, and down 46.73% quarter-over-quarter from $343469.0 in Q3 2025.
InMed Pharmaceuticals (INM) Receivables - Net (2020 - 2025) Analysis & Trends
InMed Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $182967.0 for Q4 2025.
- On a quarterly basis, Receivables - Net fell 30.32% year-over-year to $182967.0 in Q4 2025; TTM through Dec 2025 was $182967.0, a 30.32% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 5526.41% from the prior year.
- Receivables - Net fell to $182967.0 in Q4 2025 per INM's latest filing, from $343469.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $465104.0 in Q2 2025 and bottomed at $11919.0 in Q2 2021.
- The 5-year median for Receivables - Net is $76100.5 (2022), against an average of $158022.6.
- Across the five-year window, Receivables - Net tumbled 73.71% in 2021 and jumped 1240.36% in 2025, its largest moves.
- Year by year, Receivables - Net stood at $50304.0 in 2021, then jumped by 62.31% to $81647.0 in 2022, then soared by 356.69% to $372870.0 in 2023, then dropped by 29.58% to $262569.0 in 2024, then tumbled by 30.32% to $182967.0 in 2025.
- Per Business Quant, the three latest INM Receivables - Net figures stand at $182967.0 (Q4 2025), $343469.0 (Q3 2025), and $465104.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 182,967.00 |
| Dec 31, 2025 | 182,967.00 |
| Sep 30, 2025 | 343,469.00 |
| Sep 30, 2025 | 343,469.00 |
| Jun 30, 2025 | 465,104.00 |
| Jun 30, 2025 | 465,104.00 |
| Mar 31, 2025 | 367,813.00 |
| Mar 31, 2025 | 367,813.00 |
| Dec 31, 2024 | 262,569.00 |
| Dec 31, 2024 | 262,569.00 |
| Sep 30, 2024 | 284,695.00 |
| Sep 30, 2024 | 284,695.00 |
| Jun 30, 2024 | 34,700.00 |
| Jun 30, 2024 | 34,700.00 |
| Mar 31, 2024 | 207,681.00 |
| Mar 31, 2024 | 207,681.00 |
| Dec 31, 2023 | 372,870.00 |
| Dec 31, 2023 | 372,870.00 |
| Sep 30, 2023 | 66,775.00 |
| Sep 30, 2023 | 66,775.00 |